Prostate Cancer (SU2C/PCF Dream Team, 2019)

Overview

Multi-institutional metastatic castration-resistant prostate cancer (mCRPC) cohort generated by the SU2C/PCF Dream Team, profiled by whole-genome sequencing and RNA-seq. Used as a reference comparator for genomic analyses of prostate cancer and NEPC. PMID:38488813

Composition

  • 429 metastatic castration-resistant prostate cancer patients from the SU2C/PCF Dream Team consortium. PMID:38488813
  • Cancer types: prostate adenocarcinoma (PRAD) and neuroendocrine prostate cancer (PRNE). PMID:38488813
  • Used as validation cohort for cross-dataset analysis of DDR gene expression and FGFR1 expression patterns. PMID:38488813

Assays / panels (linked)

Papers using this cohort

  • PMID:38488813 — Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series.

Notable findings derived from this cohort

  • DDR-associated gene expression pattern concordant with morphologic classification confirmed in SU2C dataset; NEPC samples exhibited elevated MYCN and/or AURKA expression. PMID:38488813
  • Three FGFR1 downstream genes (NRP2, LRP4, TGFBI) preferentially expressed in bone metastases in the SU2C dataset. PMID:38488813
  • Referenced for USP10 deep deletion frequency (~10%) in metastatic castration-resistant prostate cancer, used to contextualize the therapeutic vulnerability of the USP10–TRMT10A axis PMID:28068672
  • Used (SU2C/PCF Dream Team 2019, n=266 polyA RNA-seq samples) for cross-cohort correlation of the NOL10 cell-cycle signature (CCS) with the clinical cell-cycle-progression (CCP) score, and for combined NOL10+USF1 ROC survival analyses PMID:28927585.

Sources

This page was processed by entity-page-writer on 2026-04-11. - PMID:28068672

This page was processed by wiki-cli on 2026-05-14. - PMID:28927585

This page was processed by wiki-cli on 2026-05-15.